This last week of November, Ovohorse & Ovoclone were awarded the ‘European Awards in Medicine 2024’ in the ‘Genetics’ category, thanks to their technological advancements, innovations, and the research work carried out by the Ovohorse team in their laboratories on animal cloning and cell line preservation.
‘The European Awards’ brings together professionals and experts in the field of medicine from across Europe with the aim of promoting knowledge, quality, and research. This event took place in Budapest, at Gundel Palace, Hungary’s most famous restaurant.
Ovohorse & Ovoclone, companies within the OVO Group, have a total of over 150 professionals, including embryologists, doctors, veterinarians, and researchers. The team’s expertise in assisted reproduction techniques, genetics, and cryopreservation, along with their high success rates and the quality certifications that endorse their facilities, has positioned them as one of the leading groups in reproductive medicine and cell cryopreservation.
The commitment to the application of science and the development of advanced methods has made Ovohorse & Ovoclone the first cloning and cell line preservation laboratory in Spain. These techniques enable not only the cryopreservation of samples in the genetic bank for future use but also make it possible to clone a genetically healthy and identical animal to an existing one.
Cloning encompasses various species, such as dogs, cats, horses, and camels, ultimately preserving the genetic legacy of those who played a significant role, whether in breeding, competitions, or everyday life. One of the purposes of Ovohorse & Ovoclone is to go beyond with their technology and help preserve the genetic heritage of species, thus preventing the loss of their biological diversity and contributing to environmental sustainability and global biodiversity.
The latest innovation introduced by Ovohorse & Ovoclone is an international application for the auction of equine embryos and clones with high genetic quality, allowing users to place bids from anywhere in the world.
This extensive project by the OVO Group is led by Enrique Criado Scholz, an embryologist, laboratory director, and CEO of the OVO Group, who brings a long-standing career and extensive experience in the field of reproductive medicine. Enrique was responsible for accepting the ‘The European Awards 2024’ prize.
This and the group’s other international recognitions reflect the quality and support the work in a constantly evolving field.
